MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Getinge Group and subsidiary Maquet Cardiovascular sign agreement to acquire Atrium Medical for $680 Million

Getinge Group and subsidiary Maquet Cardiovascular sign agreement to acquire Atrium Medical for $680 Million

By

— Atrium’s products strategically augment MAQUET Cardiovascular’s global business —

WAYNE, N.J., Oct. 3, 2011 /PRNewswire/ — GETINGE GROUP (STO:GETIB) and its subsidiary, MAQUET Cardiovascular, a global leading provider of cardiovascular technologies, announced today that it has signed a definitive agreement to acquire Atrium Medical Corporation for $680 million. Atrium is a leader in medical device technologies for interventional cardiology and radiology, chest trauma care and thoracic drainage, vascular surgery, and general surgery. Atrium will operate as an independent, self-contained business unit of MAQUET Cardiovascular and will be led by current Atrium president, Trevor Carlton.

“The acquisition of Atrium is an excellent strategic fit with our long-term business goals as Atrium’s robust product line complements MAQUET Cardiovascular’s existing therapy options and provides additional solutions for the customers that we serve,” said Christian Keller, president and chief executive officer of MAQUET Cardiovascular. “Like MAQUET, innovation is at the core of Atrium’s business and we believe that this acquisition will allow us to leverage the scientific and technological advances across both organizations so that we may continue to deliver ground-breaking solutions to customers and patients worldwide.”

“MAQUET Cardiovascular’s heritage and global leadership in the interventional cardiology, vascular surgery and cardiopulmonary spaces provides us the resources necessary to continue to grow our business and better serve our customers around the world,” said Trevor Carlton, president, Atrium Medical. “We believe the similarities in our cultures and business focus, coupled with our ability to continue to work independently will allow our sales team, researchers and scientists to further unlock the value of the core technologies that have driven our success to date.”

The transaction is expected to close in the fourth quarter of 2011, subject to U.S. Federal Trade Commission (FTC) approval.

About Atrium
Atrium’s vast expertise in medical device technologies for the treatment of coronary and vascular disease, chest trauma, hernia and soft tissue injury has brought a number of breakthrough advances in several diversified healthcare markets including interventional cardiology and radiology, chest trauma care and thoracic drainage, vascular surgery, and general surgery. Maintaining a commitment to the latest ISO13485 Quality Standards, state-of-the-art manufacturing and automation, cell biology and biomaterial discovery programs, Atrium continues to excel in those healthcare segments that require more advanced surgical intervention for improvements in patient outcomes. For more information please visit www.atriummed.com.

About MAQUET
As a trusted partner for hospitals and clinicians since 1838, MAQUET is a global leader in medical systems that advance surgical interventions, cardiovascular procedures and critical care. MAQUET develops and designs innovative products and therapeutic applications for the operating room, hybrid OR/cath lab, intensive care unit and patient transport within acute care hospitals, improving outcomes and quality of life for patients.

Cardiovascular specialties include intra-aortic balloon counterpulsation (IABC) therapy for cardiac assist; coronary artery bypass surgery; aortic and peripheral vascular surgery; and extracorporeal circulation. The Critical Care portfolio includes market-leading intensive care ventilators and anesthesia machines. MAQUET also equips Surgical Workplaces with critical infrastructure, such as flexible room design for OR and ICU; OR tables; lights and ceiling supply units; and OR integration for image data management.

MAQUET is a subsidiary of the publicly listed Swedish GETINGE GROUP. In 2010, MAQUET generated nearly half of the company’s annual revenue of $3.2 billion. The company has 12,000 employees worldwide, including 5,000 employees in 36 international sales and service organizations, as well as a network of more than 250 sales representatives. For more information please visit www.maquet.com and www.getingegroup.com.
MAQUET – The Gold Standard.

About Getinge
GETINGE GROUP is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. GETINGE GROUP operates under the three brands of ArjoHuntleigh, GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management solutions. GETINGE provides solutions for infection control within healthcare and contamination prevention within life sciences. MAQUET specializes in solutions, therapies and products for surgical interventions and intensive care.
The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.
SOURCE MAQUET Cardiovascular

In case you missed it

RSS From Medical Design & Outsourcing

  • A closer look at a microrobot that could treat a rare brain malformation
    Los Angeles–based startup Bionaut Labs emerged from stealth mode earlier this year to announce its intent to use drug-filled microrobots to treat certain cancers. The company has now secured a humanitarian use device designation from FDA to use a microrobot known as BNL-201 to treat Dandy-Walker syndrome, a rare brain malformation. In 1914, neurosurgeon Walter… […]
  • Heraeus buys Mo-Sci and ETS Technology Holdings
    The Heraeus Group has a deal to acquire Mo-Sci Corp. and ETS Technology Holdings, the Germany-based conglomerate announced this week. Mo-Sci is a supplier of glass microspheres, fibers and powders for medical devices, while ETS is the developer of bioactive glass fiber wound care product Mirragen, an FDA-cleared resorbable synthetic skin substitute. The companies —… […]
  • Medical Alley appoints new CEO
    The Medical Alley Association announced today that it appointed Roberta Dressen as its new president and CEO. Dressen takes over the position previously held by Shaye Mandle since 2014 before he announced his departure for the Biotechnology Innovation Organization (BIO) in February. Steffen Hovard served as interim CEO in the time since then. Get the full… […]
  • Westfall Technik names Mark Gomulka as CEO
    Westfall Technik’s board of directors has nominated Mark Gomulka to lead the company. Gomulka joined the Las Vegas–based plastics manufacturer as SVP in January 2020. Before that, he led Flex’s medical and precision plastics operations for five years and earlier spent 15 years at Nypro in various global operational and leadership roles. In those positions… […]
  • The MedTech Conference by AdvaMed to be a mixture of in-person and virtual
    To hold an event or not to hold a live event. Medtech trade association AdvaMed chose both for The Medtech Conference, which takes place next week. The September 27–30 conference includes a mixture of virtual presentations and in-person events in Washington, D.C., and Minneapolis. AdvaMed CEO Scott Whitaker mentioned several conference agenda highlights during a… […]
  • Varta launches online battery monitoring feature
    Battery maker Varta has launched a cloud computing feature to let customers remotely monitor battery charging, health and the temperature of the battery management system. While Varta makes microbatteries for medical devices such as hearing aids, the new online monitoring dashboard is meant for its “Easy Block” and “Easy Blade” modular smart batteries. The smart… […]
  • Bionaut Labs wins humanitarian use device designation to treat rare pediatric brain disorder
    Microrobotics startup Bionaut Labs has announced that FDA has granted a humanitarian use device designation for the device known as BNL-201 to treat Dandy-Walker syndrome, a congenital brain malformation affecting the cerebellum. According to the National Organization for Rare Disorders, the syndrome affects one out of every 25,000 to 35,000 live births. There are currently… […]
  • Integer plans $30 million innovation and manufacturing facility in Galway
    Integer Holdings Corp. (NYSE: ITGR) plans to build a medical device innovation and manufacturing facility in the Parkmore East area of Galway, Ireland. Plano, Texas–based Integer said the initial phase of the project will total 60,000 square feet and a $30 million investment over the coming years, with construction scheduled from 2022 to late 2023… […]
  • Accu-Tube appoints Matthew Haddle as CEO
    Accu-Tube today announced that it has appointed Matthew Haddle as its new CEO. Prior to joining the Englewood, Colorado-based company, Haddle was GM of industrial coating services and equipment at Praxair Surface Technology. He has also held senior management positions at Albany Engineered Composites and Accellent. Get the full story on our sister site, Medical… […]
  • LightDeck picks GS Plastic Optics for COVID-19 test ramp up
    LightDeck Diagnostics has selected GS Plastic Optics to make optical components for its new COVID-19 antibody testing platform. Boulder, Colorado–based LightDeck developed a screening platform to deliver results as quickly as five minutes for SARS-CoV-2 ultra-rapid antigen and COVID-19 total antibody tests, using a laser waveguide with a consumable cartridge for each testing sample.  Rochester,… […]
  • Hologic’s first Global Women’s Health Index flags preventative care for improvement
    An estimated 1.5 billion women have not been tested in the past year for critical diseases, according to Hologic’s first Global Women’s Health Index. On behalf of diagnostic maker Hologic, the Gallup World Poll surveyed more than 60,000 women and girls (age 15 and older) across the world to measure action and attitudes about women’s… […]

Leave a Reply